Table 1.
Characteristics of studies included in the meta-analysis
| Study, year | Type of study | Country | Publication status | NMV-r vs no NMV-r, n | Age in years – NMV-r vs no NMV-r | Females – NMV-r vs no NMV-r, n (%) | Vaccinated group – NMV-r vs no NMV-r, n (%) | Vaccination status | Contributions to a total of sample size, % |
|---|---|---|---|---|---|---|---|---|---|
| Bajema et al., 2022 [21] |
OS |
USA |
Preprint |
1587 vs 1587 |
65.0 (54.0-74.0), 66.0 (54.0-74.0)† |
175 (11.0) vs 171 (10.7) |
1126 (71.0) vs 1108 (69.8) |
Not fully vaccinated |
1.00 |
| Dryden-Peterson et al., 2022 [19] |
OS |
USA |
Publication |
12 541 vs 32 010 |
NR§ |
7294 (58.0) vs 19 422 (61.0) |
11 859 (91.0) vs 28 377 (91.0) |
Fully vaccinated* |
17.94 |
| Ganatra et al., 2022 [8] |
OS |
USA |
Publication |
1130 vs 1130 |
57.5 (16.3), 57.7 (16.3)‡ |
712 (63.0) vs 724 (64.1) |
1130 (100.0) vs 1130 (100.0) |
Fully vaccinated |
1.01 |
| Wong et al., 2022 [16] |
OS |
China |
Publication |
890 vs 890 |
77.0 (14.2), 77.8 (15.8)‡ |
443 (49.8) vs 436 (49.0) |
93 (10.4) vs 102 (11.5) |
Fully vaccinated |
0.09 |
| Wong et al., 2022 [17] |
OS |
China |
Publication |
5542 vs 54 672 |
NR§ |
2976 (53.7) vs -29182 (53.4) |
1850 (33.4) vs 18 138 (33.2) |
Fully vaccinated |
8.91 |
| Zhou et al., 2022 [18] |
OS |
USA |
Preprint |
2808 vs 10 849 |
60.6 (15.8), 60.7 (15.8)‡ |
1625 (57.9) vs 6310 (58.2) |
1897 (67.6) vs 7207 (66.4) |
Not fully vaccinated |
4.06 |
| Schwartz et al. 2022 [15] | OS | Canada | Preprint | 8876 vs 168 669 | 74.3, 74.4¶ | 5263 (59.3) vs 100 189 (59.4) | 7527 (84.8) vs 142 694 (84.6) | Fully vaccinated | 66.99 |
OS – observational study, USA – United States of America, NMV-r – nirmatrelvir plus ritonavir
*Fully vaccinated: received at least two doses of a vaccine.
†Age was expressed as medians and interquartile ranges.
‡Age was expressed as means and standard deviations.
§Age was presented in age groups only.
¶Age presented as means, but without standard deviations.